Nicoline van der Maas
Overview
Explore the profile of Nicoline van der Maas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
287
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Bruin O, Phijffer E, Ahmadizar F, van der Maas N, Wildenbeest J, Sturkenboom M, et al.
BMJ Glob Health
. 2023 Oct;
8(10).
PMID: 37899087
Introduction: Maternal vaccination is a promising strategy to reduce the burden of vaccine-preventable diseases for mothers and infants. We aimed to provide an up-to-date overview of the efficacy and safety...
2.
Middeldorp M, van Lier A, van der Maas N, Veldhuijzen I, Freudenburg W, Van Sorge N, et al.
Vaccine
. 2021 Jan;
39(7):1039-1043.
PMID: 33478793
We aimed to assess the impact of the COVID-19 pandemic on the incidence of vaccine-preventable diseases (VPDs) and participation in the routine infant vaccination programme in the Netherlands. The incidence...
3.
Htar M, de Ridder M, Braeye T, Correa A, McGee C, de Lusignan S, et al.
Vaccine
. 2019 Nov;
38 Suppl 2:B31-B37.
PMID: 31677949
The Accelerated Development of VAccine benefit-risk Collaboration in Europe (ADVANCE), a public-private consortium, implemented and tested a distributed network system for the generation of evidence on the benefits-risks of marketed...
4.
Nic Lochlainn L, de Gier B, van der Maas N, van Binnendijk R, Strebel P, Goodman T, et al.
Lancet Infect Dis
. 2019 Sep;
19(11):1246-1254.
PMID: 31548081
Background: Vaccinating infants with a first dose of measles-containing vaccine (MCV1) before 9 months of age in high-risk settings has the potential to reduce measles-related morbidity and mortality. However, there...
5.
Nic Lochlainn L, de Gier B, van der Maas N, Strebel P, Goodman T, van Binnendijk R, et al.
Lancet Infect Dis
. 2019 Sep;
19(11):1235-1245.
PMID: 31548079
Background: Measles is an important cause of death in children, despite the availability of safe and cost-saving measles-containing vaccines (MCVs). The first MCV dose (MCV1) is recommended at 9 months...
6.
Weibel D, Sturkenboom M, Black S, de Ridder M, Dodd C, Bonhoeffer J, et al.
Vaccine
. 2018 Aug;
36(41):6202-6211.
PMID: 30122647
Background: In 2010, a safety signal was detected for narcolepsy following vaccination with Pandemrix, an AS03-adjuvanted monovalent pandemic H1N1 influenza (pH1N1) vaccine. To further assess a possible association and inform...
7.
Kemmeren J, Honsbeek M, Dijkstra F, de Lange M, van der Maas N, Smallenburg R, et al.
Vaccine
. 2016 Jun;
34(34):3961-6.
PMID: 27349839
Background: During the 2009/2010 season, information on adverse events after administration of seasonal and pandemic influenza vaccines was collected by different active surveys in the Netherlands. In the present paper,...
8.
Kristensen M, van Lier A, Eilers R, McDonald S, Opstelten W, van der Maas N, et al.
Vaccine
. 2016 Jan;
34(7):942-9.
PMID: 26752065
Background: Implementation of additional targeted vaccinations to prevent infectious diseases in the older adults is under discussion in different countries. When considering the added value of such preventive measures, insight...
9.
McDonald S, Teunis P, van der Maas N, de Greeff S, de Melker H, Kretzschmar M
BMC Infect Dis
. 2015 Dec;
15:588.
PMID: 26715486
Background: Despite high vaccination coverage, infection with Bordetella pertussis is a current public health concern in the Netherlands and other European Union member states. Because surveillance data are subject to...
10.
Donken R, van der Maas N, Swaan C, Wiersma T, Te Wierik M, Hahne S, et al.
BMC Fam Pract
. 2014 Jun;
15:112.
PMID: 24910158
Background: The Dutch National Immunisation Programme includes six tetanus toxoid (TT) vaccinations and reaches a high rate of vaccination coverage. In the Netherlands, several guidelines related to tetanus post-exposure prophylaxis...